← All trials
NCT00411723
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2006
- Primary completion
- Feb 1, 2009
- Completion date
- May 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 34
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Artielle ImmunoTherapeuticsLead sponsor
- University of MarylandOverall official - principal investigator
- EvergreenHealthOverall official - principal investigator
- Oregon Health and Science UniversityOverall official - principal investigator
- Indiana UniversityOverall official - principal investigator
- Yale UniversityOverall official - principal investigator
- University of KansasOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.